Search Beyond News…

Rosen Law Firm intensifies securities fraud litigation campaign with lead-plaintiff deadlines converging in September-October 2026 across multiple NASDAQ-listed companies

Executive summary: Rosen Law Firm issued a reminder on August 26, 2026 that PRCT investors with losses exceeding $100K have until September 22, 2026 to apply as lead plaintiffs in a securities fraud class action covering purchases between February 28, 2024 and February 25, 2026. The case alleges violations of securities laws by PROCEPT BioRobotics Corporation. The lawsuit affects shareholders who traded during a two-year class period and could result in significant financial liability for PROCEPT, while also influencing investor sentiment in the medical robotics sector. The convergence of multiple class actions filed by the same firm on the same day signals a wave of securities litigation across the broader market.

Who is involved: PROCEPT BioRobotics Corporation (NASDAQ: PRCT), Rosen Law Firm, Hagens Berman Sobol Shapiro LLP, DJS Law Group, ClaimsFiler, Glancy Prongay Wolke & Rotter LLP, Kessler Topaz Meltzer & Check LLP, Gross Law Firm, Law Offices of Howard G. Smith.

Likely next (inference): The September 22, 2026 lead plaintiff deadline will likely determine the lead plaintiff and counsel structure for the consolidated PRCT class action. Court filings and motions to consolidate are expected after that date.

Rosen Law Firm has issued another reminder for investors who purchased PROCEPT BioRobotics (NASDAQ: PRCT) stock between February 28, 2024 and February 25, 2026 to file as lead plaintiffs in a securities fraud class action by September 22, 2026. The announcement is the latest in a series of at least ten legal notices filed by multiple law firms since August 17, 2026, all targeting the same company and class period. The same day, Rosen Law also published lead-plaintiff deadline reminders for at least five other companies — Hertz Global, Wix.com, Datavault AI, Park Ha Biological Technology, and Smartsheet — signaling a coordinated batch of class-action filings across diverse sectors.

What's next — scenarios

Inference: scenarios and probabilities are Beyond's assessment, not reported fact.

Coordinated Litigation Escalation (50%)

Increased legal defense costs and potential settlement reserves impacting PRCT cash flow.

Regulatory or Judicial Dismissal (30%)

Potential relief for PRCT stock price if motion to dismiss is granted by courts.

Systemic Litigation Contagion (20%)

Wider volatility in NASDAQ tech and biotech sectors as multiple targeted firms face simultaneous legal pressure.

What to watch

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →